Results 171 to 180 of about 2,169 (197)

Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA)

Expert Opinion on Investigational Drugs, 2022
Theodora Markati, Gemma Fisher, Sithara Ramdas   +2 more
exaly  

Risdiplam: new opportunities but more to be done

The Lancet Neurology, 2022
openaire   +2 more sources

Risdiplam bei präsymptomatischen Säuglingen mit SMA

NeuroTransmitter, 2022
openaire   +1 more source

Positive Langzeitdaten für Risdiplam bei SMA

InFo Neurologie + Psychiatrie, 2023
openaire   +1 more source

Beschleunigtes Zulassungsverfahren für Risdiplam

Pädiatrie, 2020
openaire   +1 more source

New results for risdiplam in spinal muscular atrophy

The Lancet Neurology, 2022
openaire   +2 more sources

Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy

Clinical Pharmacology and Therapeutics, 2021
Yumi Fukushima, Michael Gertz, Leon Aarons   +2 more
exaly  

Risdiplam bei spinaler Muskelatrophie Typ 1

Monatsschrift Kinderheilkunde, 2021
openaire   +1 more source

Children With Spinal Muscular Atrophy Treated With Nusinersen/Risdiplam

D105. OVERCOMING OBSTACLES: APPROACHES TO PEDIATRIC SLEEP SCREENING AND TREATMENT, 2023
A. Chacko, P.D. Sly, S. Deegan, E. Young, L. Gauld   +4 more
openaire   +1 more source

Risdiplam : Aus Expertensicht

2021
Rosales, Juan Muñoz, Kölbel, Heike, Hagenacker, Tim, Schara-Schmidt, Ulrike   +3 more
openaire   +2 more sources